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ABSTRACT 
The purpose of present study was to develop RP-HPLC method for estimation of docetaxel trihydrate which should be a suitable, simple, 
precise, accurate, robust, and reproducible. The samples were assayed by the Shimadzu HPLC instrument - LC-20AD (Japan) equipped with 
Shimadzu SPD-M20A UV-VIS detector operated at wavelength of 230 nm. The binary gradiant pump was used for the analytical method 
development. The reverse phase stainless steel column (150 × 4.6 mm) packed with 5 μm particles (C-8, LiCrosphore® 100, Germany) was 
used to take chromatograph. A mobile phase consisting of acetonitrile/phosphate buffer 20 mM, (45:55, v/v), pH 3.5 adjusted with o -
phosphoric acid at a flow rate of 1 mL/min. The method was validated by system suitability and reproducibility. The linearity was also 
determined using samples with five different concentrations of 20, 40, 60, 80 and 100 µg/mL. The results of the study showed that the 
developed RP-HPLC method is simple and robust which is useful for the estimation of docetaxel trihydrate in bulk drug and in pharmaceutical 
dosage form. The results of stability show that the method has stability over a period of 48 h at room temperature. 
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1. INTRODUCTION  
Docetaxel [4-acetoxy-2α-benzoyloxy-5β,20-epoxy-1,7β,10β-
trihydroxy-9-oxotax-11-ene-11α-yl-(2R,3S)-3-tert-butoxy-
carbonylamino-2-hydroxy-3-phenylpropionate] (see Figure 
1) is a semisynthetic antineoplastic agent which is derived 
from a natural inactive precursor 10-deacetyl baccatin III. 
This was extracted from leaves of Taxus baccata [1, 2]. 
Docetaxel is widely used chemotherapeutic agents especially 
in the breast cancer therapy [3] and it was approved by the 
United States Food and Drug Administration (USFDA) for the 
treatment of castration resistant prostate cancer (CRPC) [4]. 
It belongs to BCS Class II with practical insolubility in water 
(4.93 µg/mL) [5] and high permeability. It has a λmax of 230 
nm and hence it possesses very poor oral bioavailability [6]. 
It acts by blocking the cellular mitotic and interphase 
functions [7, 8] and its anticancer activity is dependent on its 
concentration and duration of exposure [9, 10]. Their cell 
specific activity and various targeted drug delivery were 
prepared for enhancing their efficacy and site specific action 
[11]. The pharmacokinetic and tissue distribution studies for 
DTX–loaded micelles shows significantly higher retention 
concentration in plasma and tumor tissue compared with 
free DTX [12, 13].  
The present study was aimed to develop a simple, rapid and 
robust RP-HPLC method for quantification of DTX.  The 
method was validated based on parameters like system 
suitability, specificity, robustness. The stability of developed 
method was also studied at room temperature. 
 
Figure 1: Chemical Structure of docetaxel trihydrate 
 
 
Rarokar et al                                                                                                        Journal of Drug Delivery & Therapeutics. 2019; 9(4-s):525-528  
ISSN: 2250-1177                                                                                  [526]                                                                                 CODEN (USA): JDDTAO 
2. MATERIALS AND METHOD 
2.1 Materials 
Docetaxel trihydrate (DTX) was obtained as a gift sample 
from Scino Pharmaceutical Pvt., Taiwan. HPLC grade 
acetonitrile was purchased from Thermo Fisher Scientific 
India Pvt. Ltd. o-phosphoric acid was purchase from Loba 
Chemi Pvt. Ltd. (India). Water was purified on a Milli-Q 
system obtained from a Millipore® synergy system 
(Millipore, Billerica, Massachusetts, USA). All other chemicals 
used were of analytical grade. 
2.2 Instrument and chromatographic condition 
A Shimadzu HPLC instrument - LC-20AD (Japan) equipped 
with Shimadzu SPD-M20A UV-VIS detector operated at 
wavelength of 230 nm and binary gradiant pump was used 
for the analytical method development. The reverse phase 
stainless steel column (150 × 4.6 mm) packed with 5 μm 
particles (C-8, LiCrosphore® 100, Germany) was used to 
take chromatograph. 
2.3 Preparation of mobile phase and drug sample 
2.3.1 Preparation of buffer for mobile phase  
Phosphate buffer (20 mM) pH 3.5 was prepared by 
dissolving 1.31g of sodium dihydrogenphosphate and 1.05 g 
of phosphoric acid in HPLC water. Adjust the pH 3.5 using o-
phosphoric acid. Filter the solution under reduced pressure 
to remove insoluble substance using 0.45 μm filters. 
2.3.2 Preparation of mobile phase 
A mobile phase containing acetonitrile and phosphate buffer 
(45:55, v/v) was prepared with 45% v/v acetonitrile and 
55% v/v of phosphate buffer 20 mM, pH 3.5 adjusted with o-
phosphoric acid. Sonicate for 15 min and filter through 0.45 
μm filter before use. 
2.3.3 Preparation of standard stock solution 
A stock solution of DTX was prepared by dissolving it in 
HPLC grade acetonitrile. Weighed accurately about 10 mg of 
DTX was transferred to the 10 mL volumetric flask and 
dissolve in HPLC grade acetonitrile. The volume was made 
upto 10 mL to get final concentration of 1000µg/mL for 
analyte. 
2.3.4 Preparation of sample 
A stock solution of DTX (1000 µg/mL) was used for 
subsequent dilutions to obtained five concentrations 20, 40, 
60, 80 and 100 µg/mL. The samples were appropriately 
diluted with the acetonitrile to obtained desired 
concentrations and filtered through a 0.22 µm pore size filter 
before injection. 
2.4 Method development  
DTX concentration was measured using HPLC analysis (SPD-
M20A Shimadzu pump, LC-20AD Shimadzu UV-vis detector) 
at 230 nm. The samples were chromatographed on a 150 × 
4.6 mm reverse phase stainless steel column packed with 5 
μm particles (C-8, LiCrosphore® 100, Germany) and eluted 
with a mobile phase consisting of acetonitrile/phosphate 
buffer 20 mM, (45:55, v/v), pH 3.5 adjusted with o-
phosphoric acid at a flow rate of 1 mL/min. The column 
temperature was maintained at 25 ºC. The samples were 
appropriately diluted with acetonitrile and injected (20 μL) 
directly into the injector of HPLC system with the help of 
syringe without further treatment.  
2.5 Validation of the RP-HPLC method 
2.5.1 System suitability 
The system suitability was assured by determining peak 
retention time, peak area, theoretical plates and tailing factor 
for DTX. The prescribed values for system suitability are CV < 
1%, asymmetry factor < 2 and theoretical plates >2000 [14]. 
The standard concentration of 1000 µg/mL was used in the 
preparation of the samples. The sample preparation was 
done according to the method described in Section 2.3; 
therefore, the final nominal concentration, to be detected by 
the described method, was 20 µg/mL. The samples were 
assayed for determining the system suitability in replicates 
of six [14]. 
2.5.2 Linearity 
The calibration curve for DTX was prepared in mobile phase 
consisting of acetonitrile/phosphate buffer 20 mM, (45:55, 
v/v) having pH 3.5 with concentrations of 20, 40, 60, 80 and 
100 μg/mL at a wavelength of 230 nm. Five standard 
concentrations of 20, 40, 60, 80 and 100 μg/mL were used in 
the linearity study of samples of DTX. All the samples were 
prepared according to the method as described above in 
Section 2.3. The slope, intercept and correlation coefficient 
(r2) were calculated for regression analysis of DTX. As per 
FDA guidelines 15% deviation from the nominal 
concentrations is permissible, except at LLOQ deviation 
should not be more than 20%. 
2.6. Stability 
The standard with 100 μg/mL concentration was used in the 
preparation of samples for testing the stability. The samples 
were prepared in accordance with the method as described 
above in Section 2.3; therefore, the final nominal 
concentration was 20 μg/mL. The stability of DTX in the 
prepared sample was determined by analysing concentration 
at 1, 6, 12, 24 and 48 h. The concentration was determined 
for DTX at each time point (n = 3). 
3. RESULT AND DISCUSSION 
HPLC method development was done in mobile phase 
consisting of acetonitrile/phosphate buffer 20 mM, (45:55, 
v/v), pH 3.5 adjusted with o-phosphoric acid, with this 
mobile phase satisfactory resolution between solvent and 
drug peaks was obtained. The flow rate of 1 mL/min was 
selected because of its ideal retention time, proper resolution 
and lesser time for analysis. Under these chromatographic 
conditions the elution of docetaxel trihydrate was observed 
to be optimum. The drug was eluted at retention time (RT) 
4.6 with peak intensity 45 at 230 nm with peak tailing about 
2.05 ± 0.55 which confirms the system suitability, as shown 
in Figure 2. 
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Figure 2: Standard chromatogram of docetaxel trihydrate 
Table 1: System Suitability for docetaxel trihydrate method development 
             
The detector response was found to be linear in the range. 
Using the MS Excel the trendline was plotted, with the 
regression line equation (slope and intercept) and data 
analyzed. The areas under curve values obtained are shown 
in Table 2. The calibration of the peak area against 
concentration of DTX was found to be y=11226x+15282 
with r² = 0.993 for the DTX concentrations of 20, 40, 60, 80 
and 100 μg/mL (where y: peak area and x: DTX 
concentration) as shown in Figure 3, the detector response 
was linear in the concentration of 0-100 µg/mL and the limit 
of detection was found to be 0.03 μg/mL. 
Table 2: Area under curve data of linearity of response for 
docetaxel trihydrate 
Sr. No. Concentration (μg/mL) AUC 
01 20 283425 
02 40 355648 
03 60 483421 
04 80 606008 
05 100 719551 
 
 
Figure 3: Calibration curve for DTX by HPLC method 
The stability of developed RP-HPLC method was performed 
at room temperature for period of 48 h. The results of 
concentrations obtained on various time point of 1, 6, 12, 24 
and 48 shows that there was no significant difference in 
concentrations at various time point. Hence the developed 
method was found to be suitable and having stability at 
room temperature. 
4. CONCLUSION 
The present RP-HPLC method for quantification of DTX 
proved to be simple, robust and reproducible as per the FDA 
guidelines. The analyte was found to be stable in the samples 
kept at room temperature for 48 h. Hence the developed 
method can be used for estimation in various dosage form 
and analysis of DTX. 
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